RA
VYGR icon

Royce & Associates’s Voyager Therapeutics VYGR Stock Holding History

Royce & Associates’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,738
Closed -$16K – 1223
2020
Q1 		$16K Buy
1,738
+202
+13% +$2.32K ﹤0.01% 1109
2019
Q4 		$21K Buy
1,536
+116
+8% +$1.69K ﹤0.01% 1097
2019
Q3 		$24K Buy
+1,420
New +$29.8K ﹤0.01% 1109

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Royce & Associates's VYGR Position: Q2 2020 in Review

Royce & Associates sold out of Voyager Therapeutics (VYGR) in Q2 2020, closing a stake of 1,738 shares — an estimated $16K sold.

Royce & Associates first reported a position in VYGR in Q3 2019 and held it in 3 quarters. The position peaked at $24K in Q3 2019. 113 funds tracked by Wall St. Rank hold VYGR as of Q2 2020.

  • Royce & Associates reported no remaining Voyager Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Royce & Associates sold 1,738 Voyager Therapeutics shares in Q2 2020, an estimated $16K.
  • Royce & Associates first reported a position in Voyager Therapeutics in Q3 2019 and held it in 3 quarters.
  • Royce & Associates's Voyager Therapeutics position peaked at $24K in Q3 2019.
  • 113 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2020.

Based on Royce & Associates's 13F filing for Q2 2020, filed 7 Aug 2020.